Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)

Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)

Background: Metastatic soft tissue sarcoma (STS) are a heterogeneous group of malignancies which are not curable with chemotherapy alone. Therefore, understanding the molecular mechanisms of sarcomagenesis and therapy resistance remains a critical clinical need. ASPP2 is a tumor suppressor, that fun...

Full description

Bibliographic Details
Main Authors: Fend, F. (Author), Kampa-Schittenhelm, K.M (Author), Lopez, C.D (Author), Overkamp, M. (Author), Rothermundt, C. (Author), Schittenhelm, M.M (Author), Tsintari, V. (Author), Walter, B. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Alternative splicing
Apoptosis
ASPP2κ
Oncogenes
p53
Rhabdomyosarcoma
Soft tissue sarcoma
Therapy resistance
Tumor suppressor
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items